Last reviewed · How we verify
Amlodipine 5 or 10 mg(oral)
Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure.
Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure. Used for Hypertension, Chronic stable angina, Vasospastic angina (Prinzmetal's angina).
At a glance
| Generic name | Amlodipine 5 or 10 mg(oral) |
|---|---|
| Also known as | Lacidipine 4 or 6 mg (oral) |
| Sponsor | GlaxoSmithKline |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits the influx of calcium ions through L-type calcium channels in the cell membrane of vascular smooth muscle and myocardium. This reduces intracellular calcium concentration, preventing smooth muscle contraction and leading to vasodilation of coronary and peripheral arteries. The result is decreased peripheral vascular resistance and reduced blood pressure, with additional anti-anginal effects through improved coronary blood flow.
Approved indications
- Hypertension
- Chronic stable angina
- Vasospastic angina (Prinzmetal's angina)
Common side effects
- Peripheral edema
- Headache
- Flushing
- Fatigue
- Dizziness
- Palpitations
Key clinical trials
- Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension (NA)
- An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) (PHASE3)
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (PHASE3)
- Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (PHASE4)
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study (PHASE4)
- Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension (NA)
- The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |